172 related articles for article (PubMed ID: 26297470)
21. Role of feasibility and pilot studies in randomised controlled trials: a cross-sectional study.
Blatch-Jones AJ; Pek W; Kirkpatrick E; Ashton-Key M
BMJ Open; 2018 Sep; 8(9):e022233. PubMed ID: 30257847
[TBL] [Abstract][Full Text] [Related]
22. Using systematic reviews to inform NIHR HTA trial planning and design: a retrospective cohort.
Bhurke S; Cook A; Tallant A; Young A; Williams E; Raftery J
BMC Med Res Methodol; 2015 Dec; 15():108. PubMed ID: 26715462
[TBL] [Abstract][Full Text] [Related]
23. Elective freezing of embryos versus fresh embryo transfer in IVF: a multicentre randomized controlled trial in the UK (E-Freeze).
Maheshwari A; Bell JL; Bhide P; Brison D; Child T; Chong HY; Cheong Y; Cole C; Coomarasamy A; Cutting R; Hardy P; Hamoda H; Juszczak E; Khalaf Y; Kurinczuk JJ; Lavery S; Linsell L; Macklon N; Mathur R; Pundir J; Raine-Fenning N; Rajkohwa M; Scotland G; Stanbury K; Troup S; Bhattacharya S
Hum Reprod; 2022 Mar; 37(3):476-487. PubMed ID: 34999830
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Recommendations and Use of Cardiovascular Risk Equations by Health Technology Assessment Agencies and Clinical Guidelines.
Betts MB; Milev S; Hoog M; Jung H; Milenković D; Qian Y; Tai MH; Kutikova L; Villa G; Edwards C
Value Health; 2019 Feb; 22(2):210-219. PubMed ID: 30711066
[TBL] [Abstract][Full Text] [Related]
25. Review of the role of NICE in promoting the adoption of innovative cardiac technologies.
Groves PH; Pomfrett C; Marlow M
Heart; 2018 Nov; 104(22):1817-1822. PubMed ID: 29773657
[TBL] [Abstract][Full Text] [Related]
26. Clinical trial metadata: defining and extracting metadata on the design, conduct, results and costs of 125 randomised clinical trials funded by the National Institute for Health Research Health Technology Assessment programme.
Raftery J; Young A; Stanton L; Milne R; Cook A; Turner D; Davidson P
Health Technol Assess; 2015 Feb; 19(11):1-138. PubMed ID: 25671821
[TBL] [Abstract][Full Text] [Related]
27. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
[TBL] [Abstract][Full Text] [Related]
28. Health technology assessment in England and Wales.
Stevens A; Milne R
Int J Technol Assess Health Care; 2004; 20(1):11-24. PubMed ID: 15176173
[TBL] [Abstract][Full Text] [Related]
29. The Role of Noncomparative Evidence in Health Technology Assessment Decisions.
Griffiths EA; Macaulay R; Vadlamudi NK; Uddin J; Samuels ER
Value Health; 2017 Dec; 20(10):1245-1251. PubMed ID: 29241883
[TBL] [Abstract][Full Text] [Related]
30. Updated recommendations: an assessment of NICE clinical guidelines.
Martínez García L; McFarlane E; Barnes S; Sanabria AJ; Alonso-Coello P; Alderson P
Implement Sci; 2014 Jun; 9():72. PubMed ID: 24919856
[TBL] [Abstract][Full Text] [Related]
31. Is the National Institute for Health and Care Excellence (NICE) in England more 'innovation-friendly' than the Federal Joint Committee (G-BA) in Germany?
Schaefer R; Schlander M
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):453-462. PubMed ID: 30556745
[No Abstract] [Full Text] [Related]
32. When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidance.
Longworth L; Youn J; Bojke L; Palmer S; Griffin S; Spackman E; Claxton K
Pharmacoeconomics; 2013 Feb; 31(2):137-49. PubMed ID: 23329429
[TBL] [Abstract][Full Text] [Related]
33. Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme.
Walters SJ; Bonacho Dos Anjos Henriques-Cadby I; Bortolami O; Flight L; Hind D; Jacques RM; Knox C; Nadin B; Rothwell J; Surtees M; Julious SA
BMJ Open; 2017 Mar; 7(3):e015276. PubMed ID: 28320800
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms and pathways to impact in public health research: a preliminary analysis of research funded by the National Institute for Health Research (NIHR).
Boulding H; Kamenetzky A; Ghiga I; Ioppolo B; Herrera F; Parks S; Manville C; Guthrie S; Hinrichs-Krapels S
BMC Med Res Methodol; 2020 Feb; 20(1):34. PubMed ID: 32075580
[TBL] [Abstract][Full Text] [Related]
35. A novel approach to sharing all available information from funded health research: the NIHR Journals Library.
Wright D; Williams E; Bryce C; le May A; Stein K; Milne R; Walley T
Health Res Policy Syst; 2018 Jul; 16(1):70. PubMed ID: 30064444
[TBL] [Abstract][Full Text] [Related]
36. Returns on Research Funded Under the NIHR Health Technology Assessment (HTA) Programme: Economic Analysis and Case Studies.
Guthrie S; Hafner M; Bienkowska-Gibbs T; Wooding S
Rand Health Q; 2016 May; 5(4):5. PubMed ID: 28083415
[TBL] [Abstract][Full Text] [Related]
37. The completeness of intervention descriptions in published National Institute of Health Research HTA-funded trials: a cross-sectional study.
Douet L; Milne R; Anstee S; Habens F; Young A; Wright D
BMJ Open; 2014 Jan; 4(1):e003713. PubMed ID: 24384896
[TBL] [Abstract][Full Text] [Related]
38. Is NICE infallible? A qualitative study of its assessment of treatments for attention-deficit/hyperactivity disorder (ADHD).
Schlander M
Curr Med Res Opin; 2008 Feb; 24(2):515-35. PubMed ID: 18186971
[TBL] [Abstract][Full Text] [Related]
39. Transparency in practice: Evidence from 'verification analyses' issued by the Polish Agency for Health Technology Assessment in 2012-2015.
Ozierański P; Löblová O; Nicholls N; Csanádi M; Kaló Z; McKee M; King L
Health Econ Policy Law; 2019 Apr; 14(2):182-204. PubMed ID: 29307327
[TBL] [Abstract][Full Text] [Related]
40. Assessing the impact of England's National Health Service R&D Health Technology Assessment program using the "payback" approach.
Raftery J; Hanney S; Green C; Buxton M
Int J Technol Assess Health Care; 2009 Jan; 25(1):1-5. PubMed ID: 19126245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
